Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:35:20 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:KPTI - KARYOPHARM THERAPEUTICS INC - http://www.karyopharm.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
KPTI - Q2.01.12·1.240.11.17-0.11-8.61,440.81,5983,1961.26  1.305  1.134.11  0.617417:06:43Apr 0115 min RT 2¢

Recent Trades - Last 10 of 3196
Time ETExPriceChangeVolume
17:06:43Q1.19-0.09127
16:53:55Q1.20-0.081
16:20:00Q1.17-0.111,300
16:05:17Q1.15-0.131
16:00:01Q1.17-0.11660
16:00:01Q1.17-0.111,600
16:00:01Q1.17-0.112,240
16:00:01Q1.17-0.114,696
16:00:01Q1.17-0.11567
16:00:01Q1.17-0.1128

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 16:05U:KPTINews ReleaseKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
2024-03-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-29 07:30U:KPTINews ReleaseKaryopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
2024-02-22 07:00U:KPTINews ReleaseKaryopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
2024-02-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:30U:KPTINews ReleaseKaryopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
2024-01-03 07:00U:KPTINews ReleaseKaryopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 20:15U:KPTINews ReleaseKaryopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Na ƒ ¯ve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(
2023-12-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:05U:KPTINews ReleaseKaryopharm to Participate at Upcoming Investor Conferences
2023-11-06 07:00U:KPTINews ReleaseKaryopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
2023-11-02 09:20U:KPTINews ReleaseKaryopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
2023-11-02 07:30U:KPTINews ReleaseKaryopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-10-30 08:00U:KPTINews ReleaseKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD ¢ „ ¢ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
2023-10-26 07:00U:KPTINews ReleaseKaryopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
2023-10-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-26 07:00U:KPTINews ReleaseKaryopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
2023-09-05 16:05U:KPTINews ReleaseKaryopharm to Participate at Upcoming Investor Conferences